Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 601–700 of 892
Lodise, T. P., Garey, K. W., Aram, J. A., & Nathanson, B. H. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad703 · Cited by 4
Management of invasive fungal infections in the pediatric intensive care unit
Fisher, B. T., Zaoutis, T. E., & Chiotos, K. (2015) · Journal of Pediatric Intensive Care · doi:10.3233/pic-14108 · Cited by 4
“candidemia [104, 105].”
Are Echinocandins Better Than Azoles for Invasive Candidiasis?
Revankar, S. G., & Sobel, J. D. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0124-8 · Cited by 4
“comparing anidulafungin to fluconazole for invasive candidiasis and candidemia clearly showed non-inferiority of the echinocandin, with a suggestion of superiority [24].”
Innovative Antimykotika zur Therapie invasiver Pilzinfektionen
Glöckner, A. (2011) · Der Internist · doi:10.1007/s00108-011-2873-9 · Cited by 5
BASES DA RESISTÊNCIA ANTIFÚNGICA: UMA REVISÃO COMENTADA
Berto, C., Wirth, F., Barth, N., & Hermes, D. M. (2018) · Revista Uningá · doi:10.46311/2318-0579.55.euj773 · Cited by 15
The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections
Veselov, A. V. (2020) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2020.3.197-209 · Cited by 8
Pecho, T., & Zeitlinger, M. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01327-2 · Cited by 6
“The main phase III study compared anidulafungin and fluconazole [39].”
BackgroundPilmis, B., Yang, Z., Lanternier, F., & Lortholary, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00049-6 · Cited by 6
Komorowski, A. S., Bai, A. D., Cvetkovic, A., Mourad, O., Lo, C. K. L., Li, X. X., Mokashi, V., Findlater, A. R., Duncan, D. B., Fuller, C., et al. (2022) · PubMed · doi:10.1128/aac.01627-21 · Cited by 1
Anidulafungin: advantage for the newcomer?
Rüping, M. J. G. T., Vehreschild, J. J., Farowski, F., & Cornely, O. A. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.207 · Cited by 4
Cross, D. M., Chmielewski, G., Lewis, E. M., Liu, L., Modesitt, M. S., Ripp, S. L., Sawaryn, C. M., & Bowman, C. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.02.004 · Cited by 4
Mucocutaneous and Deeply Invasive Candidiasis
Shoham, S., Nucci, M., & Walsh, T. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00088-4 · Cited by 4
Self-citationTreatment of invasive fungal infections in intensive care units with micafungin: The MYRIADE study
Timsit, J., Leverger, G., Milpied, N. J., & Gachot, B. (2020) · Mycoses · doi:10.1111/myc.13060 · Cited by 6
“Median (range) 10 (1-49) 6 (2-13) 8 (1-137)”
Groll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 6
Self-citationColombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(12)70336-7 · Cited by 6
Recomendaciones para el manejo de la candidemia en adultos en América Latina
Nucci, M., Thompson-Moya, L., Guzmán-Blanco, M., Tiraboschi, I. N., Cortés, J. A., Echevarria, J. I., Sifuentes‐Osornio, J., Zurita, J., Santolaya, M. E., Matute, T. A., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.001 · Cited by 8
Steinbach, W. J., & Dvorak, C. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00295-6 · Cited by 5
Gea‐Banacloche, J., & Wade, J. C. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_21 · Cited by 4
Potencial de anidulafungina en la terapia de receptores de trasplante de órgano sólido
Fortün, J., & Martín‐Dávila, P. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70031-7 · Cited by 4
Echinocandins - first line in invasive candidiasis: how strong is this 'strong' evidence?
Gonçalves-Pereira, J., & Póvoa, P. M. S. R. (2011) · Critical Care · doi:10.1186/cc10580 · Cited by 5
Piano, S. S., & Angeli, P. (2016) · Hepatology · doi:10.1002/hep.28443 · Cited by 4
Are Echinocandins Superior in Efficacy to Azoles?
Spellberg, B. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz772 · Cited by 4
“Andes indicated a nonsignificant trend to reduced mortality in the echinocandin arms in meta-analysis of the prior RCTs, driven primarily by 1 study comparing anidulafungin to fluconazole, in which there was a clear center effect [3].”
ResultPantothenate kinase is an effective target for antifungal therapy
Regan, J., DeJarnette, C. A., Reitler, P., Gihaz, S., Srivastava, A., Ge, W., Tucker, K. M., Peters, T. L., Meibohm, B., Mamoun, C. B., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.007 · Cited by 6
Vena, A., Bartalucci, C., Muccio, M., Tiseo, G., Muñóz, P., Cesaretti, M., Pilato, V. D., Marchese, A. E., Barbieri, R., Forniti, A., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00355-25 · Cited by 3
“This finding contrasts with two previous randomized trials that reported a higher incidence of persistent fungemia (23, 24) and a lower eradication rate (24) when FLZS-CP BSI were treated with echinocandins.”
Diagnosis and Management of Invasive Candida Infections in Critically Ill Patients
Zakhem, A. E., Istambouli, R., Jabbour, J.-F., Hindy, J.-R., Gharamti, A. A., & Kanj, S. S. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1741009 · Cited by 4
Drug repurposing for fungal infections
Mathuria, A., Ali, N., Kataria, N., & Mani, I. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.002 · Cited by 4
Clinical pharmacology of antiinfective drugs
Wade, K. C., & Benjamin, D. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00049-4 · Cited by 4
Antifungal Dosing in Critically Ill Patients
Bergman, S., Tyagi, I., & Ronald, K. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0012-z · Cited by 3
Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia
Falcone, M., Russo, A., Rosa, F. G. D., Pasero, D., Toma, L., Raponi, G., Ghezzi, M. C., & Venditti, M. (2010) · Journal of Chemotherapy · doi:10.1179/joc.2010.22.6.397 · Cited by 3
Fungal Infections in Cancer Patients
Granwehr, B. P., & Kontoyiannis, D. P. (2021) · Springer eBooks · doi:10.1007/978-3-319-74698-2_121-2 · Cited by 4
Use and outcome of empiric echinocandins in critically ill patients
Ylipalosaari, P., Ala-Kokko, T. I., Koskenkari, J. K., Laurila, J. J., Ämmälä, S., & Syrjälä, H. (2021) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13783 · Cited by 4
Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis
Jo, J., Tran, T. T., Beyda, N. D., Simmons, D., Hendrickson, J. A., Almutairi, M. S., Alnezary, F. S., Gonzales-Luna, A. J., Septimus, E. J., & Garey, K. W. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04473-w · Cited by 3
“, a favorable safety profile, and few drug-drug interactions [4, 5].”
BackgroundKhan, Z., Ahmad, S., Joseph, L., Chandy, R. G., & Theyyathel, A. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.2.97 · Cited by 3
Nikaein, D., Sharifzadeh, A., & Khosravi, A. (2018) · Journal of Herbmed Pharmacology · doi:10.15171/jhp.2018.43 · Cited by 4
“activity of antifungals is a benefit in most IFIs, especially in early stages of the disease, including systemic candidiasis, cryptococcal meningitis in HIV patients and aspergillosis in immunocompromised individuals (12,13).”
BackgroundAnidulafungin: Review of its Role in the Treatment of Invasive Candidiasis
de la Torre, P., & Reboli, A. C. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3153 · Cited by 4
Self-citationFailure of Echinocandin Therapy in the Treatment of Candida glabrata Chorioretinitis
Mousselli, H. A., & Norwood, J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31822fb437 · Cited by 3
The patient with candidemia: Treatment choices and algorithms
Pappas, P. G. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0017-z · Cited by 3
Self-citationLeitliniengerechte Therapie: Candidämie/invasive Candidiasis
Glöckner, A. (2010) · Mycoses · doi:10.1111/j.1439-0507.2009.01838.x · Cited by 7
Laderas, J. C. P. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70012-9 · Cited by 2
Double‐Blind Active‐Control Trials: Beware the Comparator You Keep
DiNubile, M. J. (2008) · Clinical Infectious Diseases · doi:10.1086/592068 · Cited by 3
“phase III trials, postlicensure studies, or clinical practice [11-15].”
BackgroundClaudio Alburquenque, O., Viviana Silva, A., Milenko Fuentes, G., Tapia, C. V., & Silva, V. (2011) · Revista chilena de infectología · doi:10.4067/s0716-10182011000600001 · Cited by 6
Anidulafungin versus Fluconazole for Invasive Candidiasis
THIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70778-0 · Cited by 3
Kumar, A. (2008) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(08)70530-6 · Cited by 3
Perfect, J. R. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399605.75891.fc · Cited by 4
Enfermedades invasoras por hongos levaduriformes en pacientes neutropénicos
Ruíz-Camps, I., & Jarque, I. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2015.11.001 · Cited by 4
Managing Infections in Patients With Hematological Malignancies
Kleinberg, M. E. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-415-5 · Cited by 5
Neoh, C. F., Şenol, E., Kara, A., Dinleyici, E. Ç., Turner, S. J., & Kong, D. C. M. (2017) · Mycoses · doi:10.1111/myc.12651 · Cited by 4
“,[3] depict the majority of the clinical caseload of IC in Turkey.”
BackgroundMethodInfluentialJoseph, M., Brady, R. L., Attridge, R. T., Cota, J. M., Horlen, C. K., Lusk, K. A., & Attridge, R. L. (2018) · Hospital Pharmacy · doi:10.1177/0018578718802583 · Cited by 3
“2%) Median number of days of treatment (IQR) 6 (4-9) 10 (5-14) Median number of days to LFT peak (IQR) 6 (3-12) 7 (3-13)”
BackgroundAnidulafungin in children: Experience in a tertiary care children’s hospital in Argentina
Rosanova, M. T., Sarkis, C., Escarrá, F., Epelbaum, C., Sberna, N., Carnovale, S., Figueroa, C., Bologna, R., & Lede, R. (2017) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2017.eng.374 · Cited by 3
Shalhoub, S., Wang, L., Ching, A., Husain, S., & Rotstein, C. (2014) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2014/983724 · Cited by 3
“The echinocandins, caspofungin (3), micafungin (11) and anidulafungin (12), have demonstrated efficacy against Candida.”
Self-citationCost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options
Ashley, E. D., Drew, R. H., Johnson, M. D., Danna, R. P., Dabrowski, D., Walker, V., Prasad, M., Alexander, B. D., Papadopoulos, G., & Perfect, J. R. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1124 · Cited by 3
Fungal and Parasitic Infections
Mattiuzzi, G. N., & Ostrosky-Zeichner, L. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-415-5_4 · Cited by 3
“Two other echinocandins, micafungin [22, 26] and anidulafungin [28, 29] have been approved for use in the United States during the past 2 years for treatment of candidemia.”
BackgroundAnidulafungina: nueva equinocandina para el tratamiento de micosis
del Palacio, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70023-8 · Cited by 6
Jarque, I., & Sanz, M. Á. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70013-0 · Cited by 2
Rux, C. E., Johnson, M. D., Grant, V. C., Katipunan, S. G., Chahine, E. B., Smith, D. J., Lockhart, S. R., Drwiega, E. N., Gubbins, P. O., & author, S. A. A. C. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70122 · Cited by 3
“This is in part due to worse outcomes observed in patients with candidemia due to a variety of Candida spp. treated with tri-azoles versus echinocandins [86, 87].”
Fresenius, M., & Heck, M. C. (2011) · Springer eBooks · doi:10.1007/978-3-642-16879-6_11 · Cited by 2
Anidulafungin treatment in a kidney transplant recipient with hepatic damage
Rosa, F. G. D., Manzione, N., Ranghino, A., Messina, M., Ottobrelli, A., Raviolo, S., Perri, G. D., & Segoloni, G. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02137.x · Cited by 2
Candidémie et candidose généralisée
Eggimann, P., & Pittet, D. (2010) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(10)50741-2 · Cited by 3
Heizmann, P., Klefisch, F.-R., & Heizmann, W. R. (2011) · Pharmacology & Pharmacy · doi:10.4236/pp.2011.24046 · Cited by 2
“albicans infections [42].”
Antimicóticos de uso sistémico: ¿Con qué opciones terapéuticas contamos?
González, A. M. R., & Cardona-Castro, N. M. (2009) · Dialnet (Universidad de la Rioja) · Cited by 2
Indication des traitements antifongiques (hors hématologie). Que montrent les données ?
Huette, P., & Dupont, H. (2019) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2019.03.004 · Cited by 2
Vianna, C. M. D. M., Mosegui, G. B. G., & Rodrigues, M. P. D. S. (2023) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202365009 · Cited by 4
Kim, J. H., Suh, J. W., & Kim, M. J. (2023) · Journal of Fungi · doi:10.3390/jof9050539 · Cited by 4
“Similarly, a prior randomized controlled trial comparing efficacy of fluconazole and anidulafungin for treatment of invasive candidiasis including candidemia also showed no significant difference in terms of mortality between the fluconazole group and the anidulafungin group [8].”
BackgroundResultWang, L., Wang, L., Liu, M., Ou, Y., Yang, L., & Chen, R. (2025) · IDCases · doi:10.1016/j.idcr.2025.e02261 · Cited by 2
“Based on the results of multiple randomized controlled studies [11 – 13], the Infectious Diseases Society of America (IDSA) recommends the use of echinocandins as the first-line treatment for patients with non-neutropenic candidemia, as they have comparable therapeutic efficacy and better…”
Andes, D. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab015 · Cited by 2
Nett, J. E., & Andes, D. R. (2010) · CRC Press eBooks · doi:10.1201/b13787-151 · Cited by 2
Maschmeyer, G., & Sandherr, M. (2009) · Der Internist · doi:10.1007/s00108-008-2267-9 · Cited by 2
Corrales, I., Cortés, J. A., Leal, A. L., Buitrago, G., Londoño, J. S. C., & Álvarez, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02007.x · Cited by 2
Rational Approach to Pediatric Antifungal Therapy
Steinbach, W. J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7185-2_16 · Cited by 2
“didiasis [46].”
Les antifongiques systémiques Partie 2 : éléments thérapeutiques
Hochart, S., Barrier, F., Durand-Joly, I., Horrent, S., Décaudin, B., & Odou, P. (2008) · Le Pharmacien Hospitalier · doi:10.1016/s0768-9179(08)74199-3 · Cited by 2
Tratamiento actual de la candidemia. Papel de anidulafungina
Almirante, B., & Pemán, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76589-3 · Cited by 2
Update on Fungal Infections – introduction
Picazo, J. J., Candel, F. J., & González‐Romo, F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70004-9 · Cited by 2
Candidemia y candidiasis generalizada
Eggimann, P., & Pittet, D. (2010) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(10)70439-4 · Cited by 2
Management of Candida infections in liver transplant recipients: current perspectives
Lingegowda, P. B., & Tan, B. H. (2014) · Transplant Research and Risk Management · doi:10.2147/trrm.s38620 · Cited by 2
“), they have an excellent side effect profile (with low potential for nephrotoxicity and hepatotoxicity), and they did very well in the early trials (achieving superiority over comparators in some of the studies).(71,72) With the availability of more antifungal drugs, several important points should be borne in mind w…”
Actualités thérapeutiques dans les infections fongiques
Germaud, P. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70015-x · Cited by 2
Update on fungemia in oncology and hematology
Carreras, E., Vázquez, L., Tudela, J. L. R., Pahisa, A., Perea, J. R. A., Rovira, M., & de la Cámara, R. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70035-0 · Cited by 2
Managing fungal and viral infections in pediatric leukemia
Hakim, H., & Shenep, J. L. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.58 · Cited by 2
Factors influencing recovery in patients with hemoblastoses and candidemia
Klyasova, G. A., Блохина, Е. В., Gracheva, A., Кравченко, С. К., Parovichnikova, E. N., Александрович, О. В., Korobova, A. G., Galstyan, G. M., & Kulikov, S. M. (2015) · Terapevticheskii arkhiv · doi:10.17116/terarkh201587777-87 · Cited by 2
“) изучена эффективность лечения ИК анидулафунгином в сравнении с флуконазолом у 245 пациентов, из которых 89% составили также больные КЕ [14].”
Principles of Antifungal Therapy
Steinbach, W. J., Cohen‐Wolkowiez, M., & Benjamin, D. K. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00225-6 · Cited by 2
Durand, M. L. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00112-0 · Cited by 2
Bustamante, B., Hidalgo, J. A. M., & Campos, P. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64113-3_2 · Cited by 3
Buljan, D. (2022) · Acta Clinica Croatica · doi:10.20471/acc.2022.61.04.11 · Cited by 2
Stevens, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00339-0 · Cited by 2
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 7
Amphotericin B in Severe Fungal Infections: A Critical Reappraisal of the Evidence
Póvoa, P. M. S. R., Gonçalves-Pereira, J., & Salluh, J. I. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0769le · Cited by 2
González, J. C. M., González, M. C., & Gil, C. L. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70028-7 · Cited by 3
“[35] (Tabla 1) han publicado recientemente un estudio multicéntrico, randomizado y doble ciego comparando dosis elevadas de anidulafungina (dosis inicial de 200 mg iv seguida de dosis de mantenimiento de 100 mg iv) con un grupo control con fluconazol (dosis inicial de 800 mg iv seguida de dosis de mantenimiento de 400…”
BackgroundInfluentialErratum to: An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2014) · Infection · doi:10.1007/s15010-013-0577-x · Cited by 2
Lashof, A. M. L. O., & Vogelaers, D. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit061 · Cited by 2
Transcriptional Regulation of Azole Antifungal Resistance and Tolerance in Candida Glabrata
Caudle, K. E. (2010) · doi:10.21007/etd.cghs.2010.0045 · Cited by 4
“Each of these drugs has been studied in esophageal candidiasis (48, 105, 218, 219) and invasive candidiasis (107, 139, 160, 173) and each has been shown to be effective in these clinical situations.”
BackgroundFungal Infections After Hematopoietic Cell Transplantation
Marr, K. A. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch86 · Cited by 2
Wade, J. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_52 · Cited by 1
Inter‐Institutional Dynamics and Impact of Fluconazole‐Resistant Candida parapsilosis
Korem, M., Reich, S., Rahav, G., Yahav, D., Weinberger, M., Novikov, A., Mizrahi, N., & Ben‐Ami, R. (2025) · Mycoses · doi:10.1111/myc.70017 · Cited by 2
“Microbiological cure was defined as elimination of Candida from 2 or more sequential blood cultures under antifungal treatment or presumed eradication if follow-up culture data were not available for a patient with a successful clinical response [29].”
Microbial infections in lymphocytic leukemia: A 12 year analysis in the Saudi population
Khateb, A. M., Barefah, A., Doha, Z. O., Albakri, M. M., Radhwi, O., Algiraigri, A. H., & Azhar, E. I. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103005 · Cited by 2
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 2
“101,102 All echinocandins of first generation are apparently similar in terms of efficacy, as head-to-head trials comparing micafungin and caspofungin found no significant difference in treatment success, time to blood culture clearance, or mortality.”
Glöckner, A., & Cornely, O. A. (2013) · Der Anaesthesist · doi:10.1007/s00101-013-2208-4 · Cited by 2
Antifungal Therapy in The ICU: The Bug, the Drug, and the Mug
Pereira, J. M., & Paiva, J. A. (2011) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-642-18081-1_47 · Cited by 2
“Only one recent randomized study suggested that an echinocandin may be superior to fluconazole as primary therapy for candidemia [42].”
BackgroundNorkin, M. N., & John, R. (2011) · InTech eBooks · doi:10.5772/22537 · Cited by 1
“In patients with IC fluconazole was found to be non-inferior and significantly better tolerated then AmpB [119] IC, but less effective than anidulafungin IC [124].”
BackgroundMikhail, M., & Weinberg, J. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511778339.004 · Cited by 1
Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
Auzinger, G. M., Playford, G., Graham, C. N., Narula, H., Charbonneau, C., Weinstein, D., Kantecki, M., Schlamm, H. T., & Ruhnke, M. (2013) · Critical Care · doi:10.1186/cc12025 · Cited by 1
Canbay, A. E., & Glöckner, A. (2013) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0262-y · Cited by 1
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.